Skip to main content
    S

    Silence Therapeutics PLC (SLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.80
    -0.03 (-0.15%)

    Market Cap: $1.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Silence Therapeutics PLC (SLN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in GBP.

    Silence Therapeutics reported revenue of GBP 559.00K for the fiscal year ended Dec 31, 2025, down 98.7% from the year before. That year, net income was GBP -88.61M with a net margin of -15851.9%, operating cash flow was GBP -62.27M and free cash flow was GBP -62.33M. The quarter ended Sep 30, 2026 had net income of GBP -12.43M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from GBP 770.00K, a compound annual decline of 3.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025559.00K-98.7%61.5%-16056.0%-15851.9%
    Dec 202443.26M+70.5%72.7%-146.4%-104.7%
    Dec 202325.38M+43.7%59.3%-195.5%-170.5%
    Dec 202217.65M+42.2%37.8%-281.9%-232.4%
    Dec 202112.41M+126.6%39.9%-369.0%-317.4%
    Dec 20205.48M+2145.5%31.3%-654.3%-594.0%
    Dec 2019244.00KN/A100.0%-9317.2%-8025.4%
    Dec 20180-100.0%N/AN/AN/A
    Dec 201716.00K-97.9%-49543.8%-89943.8%-10112.5%
    Dec 2016770.00KN/A-1031.3%-1546.2%-1096.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue559.00K43.26M25.38M17.65M12.41M5.48M244.00K016.00K770.00K
    Cost of revenue215.00K11.81M10.32M10.97M7.46M3.76MN/A9.74M7.94M8.71M
    Gross profit344.00K31.45M15.06M6.68M4.96M1.72M244.00K-9.74M-7.93M-7.94M
    Research and development67.75M67.88M44.02M35.50M30.77M20.21M13.34M9.74M7.94M8.71M
    Operating income-89.75M-63.32M-49.60M-49.76M-45.81M-35.85M-22.73M-20.57M-14.39M-11.91M
    Net income-88.61M-45.31M-43.27M-41.03M-39.41M-32.55M-19.58M-18.41M-1.62M-8.44M
    EBITDA-88.05M-49.12MN/A-39.93MN/A-35.53M-22.36M-20.17M-3.33M-11.60M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    RevenueN/A0421.29K34.00K159.00K307.20K183.71K24.33M1.14M598.00K15.70M2.10M
    Gross profitN/A-108.19K304.49K22.00K95.00K190.63K113.85K22.72M-1.63M-2.04M12.90M753.00K
    Operating income-14.22M-13.11M-15.02M-12.46M-26.24M-32.86M-36.75M-3.08M-22.54M-18.32M-5.58M-13.30M
    Net income-12.43M-12.29M-14.93M-11.77M-20.96M-37.51M-36.91M14.17M-27.01M-15.56M-2.31M-14.41M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of GBP 89.00K by 11.19M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets131.44M161.85M94.53M107.50M96.19M85.97M46.08M38.88M55.01M55.79M
    Current assets118.66M149.66M81.63M96.69M86.33M76.40M37.47M29.50M45.55M42.01M
    Cash and equivalents11.28M96.91M54.44M54.82M73.54M27.45M13.52M21.49M42.74M39.01M
    Total liabilities69.14M54.80M77.12M85.43M87.67M76.91M25.17M3.83M2.66M1.61M
    Short-term debt89.00K93.45K180.43K446.00K137.00K341.00K287.00KN/AN/AN/A
    Shareholder equity62.30M107.05M21.99M22.07M8.53M9.06M20.91M35.05M52.35M54.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets281.50M106.41M115.12M131.44M146.79M165.23M185.30M161.85M169.38M188.64M245.40M119.45M
    Total liabilities-66.48M67.94M65.72M69.14M72.73M71.08M298.04M54.80M74.87M76.13M88.98M97.45M
    Cash and equivalents247.66M72.05M5.66M11.28M82.03M41.74M64.89M96.91M61.95M109.48M142.73M68.79M
    Shareholder equity215.02M38.47M49.40M62.30M74.06M94.16M-112.74M107.05M94.52M112.51M156.43M21.99M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-62.27M-54.05M-39.35M-57.04M9.19M-10.78M1.73M-16.76M-9.60M-10.07M
    Capital expenditures55.00K168.61K45.00K545.00K1.80M514.00K9.00K188.00K173.00K537.00K
    Free cash flow-62.33M-54.22M-39.40M-57.59M7.39M-11.29M1.72M-16.95M-9.77M-10.60M
    Investing cash flow-47.99M-17.55M16.43M-20.50M11.71M9.62M-15.02M-4.83M13.01M-4.67M
    Financing cash flow15.00K113.54M25.16M52.58M41.45M15.43M5.27M341.00K48.00K-101.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-12.75M1.49M-15.60M-17.29M-10.89M-21.78M-12.31M-19.87M-19.66M-5.41M-9.14M-11.87M
    Capital expenditures33055.00K3.00K48.00K4.00K55.77K49.00K85.00K11.00K
    Free cash flow-12.75M1.49M-15.60M-17.34M-10.89M-21.83M-12.31M-19.92M-19.70M-5.49M-9.14M-11.87M
    Last 12 quarters

    Frequently Asked Questions About SLN

    What is Silence Therapeutics' annual revenue?

    Silence Therapeutics reported revenue of GBP 559.00K for the fiscal year ended Dec 31, 2025.

    How fast is Silence Therapeutics' revenue growing?

    Revenue was down 98.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -68.4%.

    Is Silence Therapeutics profitable?

    No. Silence Therapeutics reported net income of GBP -88.61M for the fiscal year ended Dec 31, 2025, with a net margin of -15851.9%.

    How much free cash flow does SLN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of GBP -62.27M minus capital expenditures of GBP 55.00K produced free cash flow of GBP -62.33M.

    How much debt does Silence Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of GBP 89.00K and cash and equivalents of GBP 11.28M.